Cancer cell biomarkers

Cancer cell biomarkers are biological molecules produced by tumor cells or the body in response to malignancy, which can be detected in blood, body fluids, or tissues [National Cancer Institute (NCI), 2023]. They encompass a wide variety of molecular entities, including proteins, DNA, RNA, and metabolites, that serve as indicators of physiological or pathological processes [NIH, 2022]. In clinical oncology, these biomarkers are utilized for a range of purposes, including population screening, differential diagnosis, and establishing a patient's prognosis [PubMed: 28267705]. Many biomarkers also act as predictive indicators, helping clinicians select the most effective targeted therapies for individual patients based on their specific molecular profile [Nature Reviews Cancer, 2017]. Furthermore, some biomarkers function as therapeutic targets themselves; for example, the HER2 protein is both a diagnostic biomarker and a target for drugs like trastuzumab [PubMed: 24335431]. Consequently, cancer cell biomarkers are the foundational elements of precision medicine, enabling personalized treatment strategies that improve patient outcomes while minimizing unnecessary toxicity.

Other names

Tumor markersCancer biomarkersOncomarkersMolecular markersClinical cancer markers

The mechanism varies significantly as biomarkers are a broad category; drugs may inhibit overexpressed protein receptors, block mutated signaling enzymes, or target immune checkpoint proteins identified as biomarkers (NCI, 2023).